Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)

Next Previous
Search
Trial Profile

Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders
  • Focus Adverse reactions; First in man; Proof of concept; Registrational
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 23 Feb 2017 Results of pooled analysis (NCT01688830, NCT01955720 and NCT02028780) published in the British Journal of Clinical Pharmacology
  • 01 Dec 2016 Results from two phase I studies (NCT01688830 and NCT02028780) assessing markers of pro-coagulant effects in healthy Caucasian and Japanese volunteers were published in the Thrombosis and Haemostasis
  • 15 Aug 2015 Results for Part 2 (reversal of the anticoagulant effect of dabigatran etexilate) published in the Lancet.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top